Skip to content
Tech News
← Back to articles

Gene therapies to fix failing hearts gain steam after years in the doldrums

read original get Gene Therapy for Heart Repair → more articles
Why This Matters

The development of gene therapies to regenerate heart tissue marks a significant breakthrough in treating heart failure, a leading cause of death worldwide. These innovative approaches could shift the focus from symptom management to actual tissue repair, offering hope for more effective and lasting treatments. However, challenges remain in proving true regeneration and ensuring safety, making this a pivotal yet cautious advancement for the industry and patients alike.

Key Takeaways

Heart-muscle cells (in close-up, artificially coloured) do not normally proliferate in adult mammals, but scientists are trying to coax them into doing so. Credit: Medimage/SPL

Scientists are developing a new wave of gene therapies to regenerate the heart — offering hope for treating heart failure, a debilitating and common condition.

The first clinical trial aimed at growing new heart-muscle cells is now under way, and companies are developing at least four other regenerative gene therapies for heart conditions.

“These are [the] first-in-human studies to take regeneration into the clinic,” says Andrew Baker, a gene-therapy researcher at the University of Edinburgh, UK, who is unaffiliated with the efforts. “It’s a very exciting time.”

Ranking the risk of heart disease

But the excitement is tempered with caution. The mammalian heart is bad at repairing itself and “is notoriously unwieldy when it comes to efforts to try to get it to regenerate”, says Sean Wu, a cardiologist at Stanford University in California. Some scientists are unconvinced that the data underpinning the existing clinical trial show true regeneration in the form of cell division. And efforts to regenerate the heart are still haunted by a controversy that led to the retraction of at least a dozen papers and the closure of a high-profile laboratory.

Developing a gene therapy in this field will be difficult, says Antonio Abbate, a cardiologist at the University of Virginia in Charlottesville. But “we have to do research because, eventually, we’ll get it right”.

A common failing

Heart failure occurs when the organ can’t pump enough blood for the body’s needs. The condition is becoming increasingly common in some nations. In the United States, for example, the prevalence is expected to rise by 50% in the next 15 years1. The few existing drugs treat symptoms without fixing the root of the problem: the heart is either too stiff to properly fill with blood or too weak to pump it.

How RNA therapies could be used to tackle the world’s biggest killer

... continue reading